On December 10, 2016, the medical and health science and technology innovation project of Chinese Academy of Medical Sciences, led by National Cardiovascular Center and Fuwai Hospital of Chinese Academy of Medical Sciences, was held in Fuwai Hospital. One hundred experts and scholars from Fuwai Hospital, International Exchange and Cooperation Center of National Health and Family Planning Commission, Department of Chronic Disease Control and Prevention of Disease Control Bureau attended the meeting. Omron, as a member of the project, sent technicians to participate in the study and provided 8,000 patients with Omron Bluetooth electronic sphygmomanometer free of charge.
At present, CVD has become the "number one killer" endangering people's health in China, and the death caused by CVD accounts for 41% of the total mortality. Hypertension has become a major risk factor for stroke and ischemic heart disease in China. In addition, there are about 270 million hypertension patients in China. With the acceleration of the aging society, the burden of hypertension in the elderly is bound to become more serious, and the prevention and treatment of hypertension in China is facing a very difficult task. As the first large-scale national multi-clinical center, randomized and open clinical study on hypertension targets in elderly Chinese patients aged 60-79 years, the project of "Study on Intervention Strategies of Hypertension Targets in elderly Chinese patients with hypertension" aims to evaluate the target blood pressure of elderly Chinese patients with hypertension in treatment, and to explore the target blood pressure under different blood pressure control levels. How to make the elderly patients with hypertension achieve more benefits of heart and brain, and formulate the best target population for blood pressure reduction, through the analysis of relevant data to avoid the risk caused by cardiovascular diseases as far as possible.
"Omron Health's mission is to contribute to a healthy and comfortable life for everyone on the planet," said Toru Onoseki, executive director of Omron Healthcare Japan. Omron has accumulated rich experience in the intervention, follow-up and research of hypertensive patients through the Japanese Great Force Study *. The purpose of participating in the STEP project is to expand and develop new technologies through clinical research, to provide safe products and services for Chinese patients, and at the same time, to reduce hypertension complications through cooperation, and to contribute to the establishment of China's own guidelines for hypertension prevention and treatment."
With the release of the Outline of the Healthy China 2030 Plan, the effective control of major health risk factors and the creation of health services in the Internet era will also be promoted. Omron will continue to contribute to the prevention and control of hypertension in China with the advantages of "sensing & control + intelligence", and provide safe, secure and intelligent services for Chinese patients with hypertension.
* The Omron Study: Omron has been supporting the world's first large-scale study of Japanese residents based on home blood pressure monitoring data, which began in 1986.
